Touchlight Launches mbDNA Platform Achieving 75% Knock-in Rates in Primary Human T Cells
Key Insights
Touchlight (search) has commercially launched mbDNA (search), a circular single-stranded DNA platform that supports gene insertions from 1 to 20 kilobases with superior knock-in efficiency compared to existing formats.
The platform consistently achieves 75% knock-in rates in primary human T cells while maintaining high cell viability across diverse cell types.
mbDNA (search) offers advantages over traditional AAV (search) vectors by providing greater design flexibility, reduced manufacturing complexity, and lower cytotoxicity due to its single-stranded circular structure.
Touchlight (search) has officially launched mbDNA (search) (megabulb DNA), a novel circular single-stranded DNA platform that represents a significant advancement in non-viral gene editing technology. The platform demonstrates superior knock-in efficiency compared to double-stranded DNA and competitor single-stranded DNA formats, consistently achieving 75% knock-in rates in primary human T cells while maintaining high cell viability.
Platform Design and Capabilities
The mbDNA (search) platform features a unique circular single-stranded DNA structure with a customizable stem region and fully user-defined sequence free of phage or bacterial elements. This design supports gene insertions ranging from 1 to 20 kilobases, significantly expanding the scope of genetic modifications possible in gene editing applications.
"Following extensive beta testing with key opinion leaders, CDMOs and pharmaceutical partners, we are proud to officially launch mbDNA (search) to the market," said Jill Makin, CSO at Touchlight (search). The market response has been notably positive, with one Key Opinion Leader describing mbDNA as "the best-in-class HDR template that exists today."
Addressing AAV Limitations
The platform addresses several limitations associated with traditional Adeno Associated Virus (AAV (search)) vectors, which have historically been the vector of choice for HDR gene-editing applications. AAV vectors face challenges including restricted payload capacity, high manufacturing costs, and lengthy production timelines. In contrast, non-viral DNA platforms like mbDNA (search) offer greater design flexibility with manufacturing processes that can scale without excessive complexity.
The single-stranded circular nature of mbDNA (search) provides additional benefits, including reduced cytotoxicity and highly improved editing efficiencies compared to existing approaches. This architecture enables the platform to function as a high-efficiency template for homology-directed repair (HDR) while offering improved tolerability.
Versatile Delivery and Applications
mbDNA (search) demonstrates compatibility with multiple delivery methods, including electroporation, nucleofection, and lipid nanoparticle formulations. This versatility positions the platform as an ideal choice for a wide range of gene-editing workflows across diverse research and therapeutic applications.
Beyond its primary function as an HDR template, mbDNA (search) can also serve as an episomal expression vector in transient non-viral gene therapy settings. The single-stranded nature of the platform promises improved tolerability in these applications, potentially expanding its utility in therapeutic development.
The commercial launch of mbDNA (search) follows extensive beta testing with key opinion leaders, contract development and manufacturing organizations, and pharmaceutical partners, indicating strong industry validation of the technology's potential impact on genetic engineering and therapeutic development.